February 19, 2026 argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
January 13, 2026 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
Follow us
Get the latest news and info via our social media channels.